Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bacteria

ABSTRACT: Clinically relevant bacteria TAILORED-Treatment

PROVIDER: PRJNA302716 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR10092042.fastq.gz	Fastqsanger.gz
	SRR10092043_1.fastq.gz	Fastqsanger.gz
	SRR12904715_1.fastq.gz	Fastqsanger.gz
	SRR12904715_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Bacteria

Project description:BRD-relevant bacteria

| PRJNA306895 | ENA

Bacteria

Project description:Clinically significant bacteria on the human skin

| PRJDB18874 | ENA

Anti-inflammatory Chromatinscape Associated with Clinically Relevant Timing of Glucocorticoid Treatment

Project description:Anti-inflammatory Chromatinscape Associated with Clinically Relevant Timing of Glucocorticoid Treatment

| PRJNA362226 | ENA

Collateral sensitivity of antibiotic resistant bacteria to antimicrobial peptides

Project description:Cationic antimicrobial peptides (CAPs) are promising novel alternatives to conventional antibacterial agents, but the overlap in resistance mechanisms between small-molecule antibiotics and CAPs is unknown. Does evolution of antibiotic resistance decrease (cross-resistance) or increase (collateral sensitivity) susceptibility to CAPs? We systematically addressed this issue by studying the susceptibilities of a comprehensive set of antibiotic resistant Escherichia coli strains towards 24 antimicrobial peptides. Strikingly, antibiotic resistant bacteria frequently showed collateral sensitivity to CAPs, while cross-resistance was relatively rare. We identified clinically relevant multidrug resistance mutations that simultaneously elevate susceptibility to certain CAPs. Transcriptome and chemogenomic analysis revealed that such mutations frequently alter the lipopolysaccharide composition of the outer cell membrane and thereby increase the killing efficiency of membrane-interacting antimicrobial peptides. Furthermore, we identified CAP-antibiotic combinations that rescue the activity of existing antibiotics and slow down the evolution of resistance to antibiotics. Our work provides a proof of principle for the development of peptide based antibiotic adjuvants that enhance antibiotic action and block evolution of resistance.

2018-03-29 | GSE96706 | GEO

Gut microbiota analysis after 3months probiotic-like bacteria or placebo treatment in subjects with metabolic syndrome

Project description:Background: Probiotic-like bacteria treatment has been described to be associated with gut microbiota modifications. Goal: To decipher if the effects of the tested probiotic-like bacteria are due to the bacteria itself or due to the effects of the bacteria on the gut microbiota. Methodology: In this study, gut microbiota has been analyzed from feces samples of subjects with metabolic syndrome and treated with one of the 2 tested probiotic-like bacteria or with the placebo during 3months.

| EGAS00001003585 | EGA

Project description:Gut microbiome of clinically relevant diseases

| PRJNA826059 | ENA

microalgae-bacteria

Project description:Microalgae-bacteria system for domestic wastewater treatment

| PRJNA807808 | ENA

Mus musculus

Project description:Anti-inflammatory Chromatinscape Associated with Clinically Relevant Timing of Glucocorticoid Treatment [ChIP-seq]

| PRJNA362230 | ENA

Mus musculus

Project description:Anti-inflammatory Chromatinscape Associated with Clinically Relevant Timing of Glucocorticoid Treatment [RNA-Seq]

| PRJNA362223 | ENA